Effects of belzutifan: A Synthesis of Findings from 16 Studies
- Home
- Effects of belzutifan
This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of belzutifan: A Synthesis of Findings from 16 Studies", please consult your doctor.
For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
Main research findings
Belzutifan is a promising drug for treating kidney cancer, particularly for patients with advanced clear cell renal cell carcinoma (RCC) who have previously received immunotherapy. 2 Belzutifan is a HIF-2α inhibitor, which means it blocks the activity of a protein called HIF-2α that helps cancer cells grow and spread. 8 This drug has shown positive results in treating VHL-associated RCC, pancreatic neuroendocrine tumors (pNETs), and central nervous system (CNS) hemangioblastomas. 16 7 6 11 5
Furthermore, combining belzutifan with other drugs, such as cabozantinib or lenvatinib, could potentially enhance its effectiveness in treating RCC, particularly in cases where immunotherapy has failed. 2 13
Belzutifan has also shown potential in overcoming resistance to anti-VEGF therapies and may even be used to treat rare conditions like the Pacak-Zhuang syndrome, which involves polycythemia and multiple paragangliomas. 13 3
Benefits and Risks
Benefits Summary
Belzutifan holds promise as a treatment for various cancers associated with VHL disease, including RCC, pNETs, and CNS hemangioblastomas. 16 11 5 Its efficacy can be further enhanced by combining it with other drugs, potentially offering better treatment outcomes. 2 13
Belzutifan may also be beneficial in addressing resistance to existing treatments like anti-VEGF therapies and can be used to treat rare disorders like the Pacak-Zhuang syndrome. 13 3
Risks Summary
Common side effects of belzutifan include anemia, fatigue, headache, dizziness, increased blood glucose levels, and nausea. 16 Belzutifan can also affect the effectiveness of some hormonal contraceptives and may harm the fetus during pregnancy. 16
Comparison between studies
Commonalities
Multiple studies have shown that belzutifan is effective in treating VHL-associated RCC. 16 7 6 11
Differences
The effects and side effects of belzutifan may vary depending on the study. 16 7 6 11
Some studies have investigated the effectiveness of belzutifan when used in combination with other medications. 2
Consistency and inconsistencies in the results
Research consistently shows that belzutifan is an effective treatment option for VHL-associated RCC. 16 7 6 11
However, there are variations in the reported effects and side effects of belzutifan across different studies. 16 7 6 11
Considerations for real-life application
Belzutifan holds potential as a valuable treatment option for patients with VHL-associated RCC and other VHL-associated tumors. 16 7 6 11
However, it is crucial to avoid belzutifan use in pregnant women and those using specific hormonal contraceptives. 16
Always consult your doctor before considering belzutifan treatment. 16
Limitations of current research
Research on belzutifan is still in its early stages. There are many unanswered questions regarding its long-term effectiveness and safety. 16 7 6 11
Further research is necessary to gain a more comprehensive understanding of belzutifan's effects. 16 7 6 11
Future research directions
More research is needed to assess the long-term efficacy and safety of belzutifan. 16 7 6 11
Further research is also needed to explore the effectiveness of belzutifan in combination with other medications. 2
Research is also needed to determine if belzutifan can overcome resistance to immunotherapy. 13
Conclusion
Belzutifan shows promise as a treatment option for various cancers associated with VHL disease, including RCC. 16 7 6 11
However, more research is needed to fully understand its effects and potential risks. 16 7 6 11
If you are considering belzutifan treatment, consult your doctor. 16
Benefit Keywords
Risk Keywords
Article Type
HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.
Author: MaYuanqing, JoyceAllison, BrandenburgOlivia, SaatchiFaeze, StevensChristina, Toffessi TcheuyapVanina, ChristieAlana, DoQuyen N, FatundeOluwatomilade, MacchiaroliAlyssa, WongSo C, WoolfordLayton, YousufQurratulain, MiyataJeffrey, CarrilloDeyssy, OnaboluOreoluwa, McKenzieTiffani, MishraAkhilesh, HardyTanner, HeWei, LiDaniel, IvanishevAlexander, ZhangQing, PedrosaIvan, KapurPayal, SchluepThomas, KannerSteven B, HamiltonJames, BrugarolasJames
Language : English
Author: ChoueiriToni K, McDermottDavid F, MerchanJaime, BauerTodd M, FiglinRobert, HeathElisabeth I, MichaelsonM Dror, ArrowsmithEdward, D'SouzaAnishka, ZhaoSong, RoyAnanya, PeriniRodolfo, VickeryDonna, TykodiScott S
Language : English
Author: KamiharaJunne, HamiltonKayla V, PollardJessica A, ClintonCatherine M, MaddenJill A, LinJasmine, ImamovicAlma, WallCatherine B, WassnerAri J, WeilBrent R, HeeneyMatthew M, VargasSara O, KaelinWilliam G, JanewayKatherine A, PeriniRodolfo F, ZojwallaNaseem J, VossStephan D, DuBoisSteven G
Language : English
Author: MaratheDhananjay D, JauslinPetra M, KleijnHuub Jan, de Miranda SilvaCarolina, ChainAnne, BatemanThomas, ShawPeter M, AbrahamAnson K, KauhEunkyung A, LiuYanfang, PeriniRodolfo F, de AlwisDinesh P, JainLokesh
Language : English
Author: ZamarudAroosa, MarianayagamNeelan J, ParkDavid J, YenerUlas, YooKelly H, MeolaAntonio, ChangSteven D
Language : English
Author: VisweswaranVysakh, PavithranKeechilat
Language : English
Author: JonaschEric, DonskovFrede, IliopoulosOthon, RathmellW Kimryn, NarayanVivek K, MaughanBenjamin L, OudardStephane, ElseTobias, MaranchieJodi K, WelshSarah J, ThamakeSanjay, ParkEric K, PeriniRodolfo F, LinehanW Marston, SrinivasanRamaprasad,
Language : English
Author: ChoiWonSeok W, BolandJulia L, KalolaAkshar, LinJianqing
Language : English
Author: FiggWilliam D, FioriniGiorgia, ChowdhuryRasheduzzaman, NakashimaYu, TumberAnthony, McDonoughMichael A, SchofieldChristopher J
Language : English
Author: MenMauranda, TsuiEdmund
Language : English
Author: PelleEleonora, Al-ToubahTaymeyah, MorseBrian, StrosbergJonathan
Language : English
Author: RenXintong, DiaoXiaotong, ZhuangJingjing, WuDalei
Language : English
Author: MotzerRobert J, SchmidingerManuela, EtoMasatoshi, SuarezCristina, FiglinRobert, LiuYanfang, PeriniRodolfo, ZhangYayan, HengDaniel Yc
Language : English
Author: TakagiToshio
Language : English
Author: NethBryan J, WebbMason J, WhiteJessica, UhmJoon H, PichurinPavel N, SenerUgur
Language : English
Author: FallahJaleh, BraveMichael H, WeinstockChana, MehtaGautam U, BradfordDiana, GittlemanHaley, BloomquistErik W, CharlabRosane, HamedSalaheldin S, MillerClaudia P, DorffSarah E, ChambersWiley A, MixterBronwyn D, DininJeannette, PierceWilliam F, RicksTiffany K, TangShenghui, DonoghueMartha, PazdurRichard, Amiri-KordestaniLaleh, IbrahimAmna, BeaverJulia A
Language : English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.